Document is current
Any future updates will be listed below
-
Authors
Li, Nan
Quan, Alex https://orcid.org/0000-0003-2332-6161
Li, Dan
Pan, Jiajia
Ren, Hua https://orcid.org/0000-0002-8809-7972
Hoeltzel, Gerard https://orcid.org/0000-0001-7267-6390
de Val, Natalia
Ashworth, Dana https://orcid.org/0000-0001-8836-3401
Ni, Weiming
Zhou, Jing
Mackay, Sean
Hewitt, Stephen M. https://orcid.org/0000-0001-8283-1788
Cachau, Raul https://orcid.org/0000-0001-9260-2102
Ho, Mitchell https://orcid.org/0000-0002-9152-5405
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (Z01 BC010891, ZIA BC010891)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 26 June 2022
Accepted: 23 March 2023
First Online: 8 April 2023
Competing interests
: M.H., N.L. and J.P. are inventors on the international patent application no. PCT/US2020/013739 (WO/2020/154150) assigned to the NIH, “High affinity monoclonal antibodies targeting glypican-1 and methods of use thereof”. D.A., W.N., J.Z. and S.M. are employees and equity partners of IsoPlexis Corporation. All authors declare no other conflicts of interest.
